Group 1 - The core viewpoint of the article highlights the overall poor performance of Hong Kong's biopharmaceutical stocks, with significant declines in major companies such as WuXi AppTec, Tigermed, and King’s Ray Biotech [1] - U.S. President Trump announced plans to reduce drug prices to 1/1400 to 1/1500 of current prices and to impose tariffs on pharmaceuticals, which could create volatility in the global pharmaceutical industry [1] - The Chinese biopharmaceutical sector faces both opportunities and challenges due to these developments, with potential short-term market fluctuations driven by uncertainty, particularly for businesses exposed to the U.S. market [1] Group 2 - In the long term, China's pharmaceutical industry may leverage its innovation and supply chain advantages to find new growth opportunities in the global pharmaceutical landscape, especially in areas like CDMO and internationalization of innovative drugs [1] - The article lists the latest prices and percentage changes for various biopharmaceutical stocks, indicating a general downward trend across the sector [1]

Core Viewpoint - The company has demonstrated significant revenue growth and has raised its full-year revenue guidance, reflecting confidence in the industry and its own future development [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 2.7 billion yuan, a year-on-year increase of 62.2%, and a net profit attributable to shareholders of 750 million yuan, up 52.7% year-on-year [1]. - The company's gross margin reached 36.1% in the first half of 2025, an increase of 4.0 percentage points year-on-year, driven by improved capacity utilization and operational efficiency [2]. Group 2: Market Position and Orders - The company's global market share is expected to rise to 22.2% by the first half of 2025, supported by a backlog of unfulfilled orders amounting to 1.33 billion USD, which is a 57.9% increase year-on-year [1]. - The company signed 37 new iCMC projects in the first half of 2025, setting a historical record, with new order amounts increasing by 48.4% year-on-year [1]. Group 3: Capital Expenditure and Growth Strategy - The company plans to increase long-term capital expenditures, with cumulative capital spending expected to exceed 7 billion yuan by 2029, focusing on expanding domestic and international production capacity [2]. - The company is actively developing new ADC and XDC businesses, completing over 2,300 early-stage research projects in the first half of 2025, with a significant portion focused on differentiated targets and new indications [2]. Group 4: Earnings Forecast and Valuation - The earnings per share forecasts for 2025-2027 have been adjusted to 1.29, 1.78, and 2.45 yuan, respectively, reflecting the company's strong growth potential as a leader in the global ADC CRDMO market [3]. - A target price of 65.82 HKD has been set using the DCF valuation method, maintaining a "buy" rating based on the company's long-term development potential [3].

Group 1 - The company reported a revenue of 2.701 billion yuan in H1 2025, representing a year-on-year increase of 62.2%, and an adjusted net profit (excluding interest income and expenses) of 733 million yuan, up 69.6% [1] - The total amount of uncompleted orders reached 1.329 billion yuan, a year-on-year increase of 57.9%, with North America accounting for over half of this total [1] - The company signed 37 new iCMC projects and won 13 iCMC projects in H1 2025, with a total of 563 clients, reflecting a 64% increase [1] Group 2 - The company plans to invest 1.56 billion yuan in capital expenditures in 2025, with total capital expenditures expected to exceed 7 billion yuan by 2029 to expand domestic and international production capacity [2] - The new production facility in Wuxi is fully operational, and the new park is expected to be operational by May 2025, with sufficient order reserves [2] - The company expects Non-GAAP net profits of 1.696 billion yuan, 2.199 billion yuan, and 2.908 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 41, 32, and 24 times [3]

Core Viewpoint - WuXi AppTec continues to experience rapid growth, with capital expenditures expected to exceed 7 billion RMB by 2029, indicating strong long-term development confidence [1][2] Group 1: Financial Projections - EPS for the years 2025, 2026, and 2027 are projected to be 1.30, 1.85, and 2.57 RMB respectively [1] - A PE ratio of 50 is applied for 2025, leading to a target price of 64.92 RMB per share, which translates to approximately 70.56 HKD per share [1] Group 2: Project and Order Growth - The number of projects in the pipeline is expanding, with 37 new comprehensive projects signed in the first half of 2025, bringing the total to 225 projects, an increase of 58 [1] - The total number of IND projects reached 103 as of June 30, 2025, marking an increase of 27 [1] - The total unfulfilled order amount stands at 1.329 billion USD, reflecting a year-on-year growth of 57.9%, with North America accounting for over half of this total [1] Group 3: Capital Expenditure and Capacity Expansion - Capital expenditures for 2025 are expected to be 1.56 billion RMB, with approximately 900 million RMB allocated to the Singapore base [2] - By 2029, total capital expenditures are projected to exceed 7 billion RMB, aimed at expanding domestic and international capacities, including conjugated solutions and payload linkers [2] - Expansion projects are underway in Wuxi and Shanghai, along with the design of a new base in Jiangyin, with expectations to double existing capacities [2] Group 4: Long-term Trends and Revenue Contribution - The company is expected to achieve a compound annual growth rate exceeding the industry average from 2024 to 2030, supported by its leading technology and delivery quality [2] - By 2030, the XDC project is anticipated to account for 20% of revenue, with M-end revenue also expected to exceed 20% [2]

Core Viewpoints - WuXi AppTec achieved revenue of 2.7 billion yuan in H1 2025, with a year-on-year growth of 62%, and an adjusted net profit of 800 million yuan, reflecting a 50% increase [1][2] - The company signed 37 new comprehensive projects in H1 2025, bringing the total to 225 projects, including 11 PPQ projects and 1 commercialization project, laying a solid foundation for future growth [1][2] - The global ADC market is expected to continue growing, with the company poised to maintain rapid growth due to expanding market share [1][4] Financial Performance - In H1 2025, the company reported a gross profit of 980 million yuan, an increase of 82% year-on-year, with a gross margin of 36.1%, up by 4 percentage points [2][3] - The net profit for H1 2025 was 750 million yuan, a 53% increase year-on-year, while the adjusted net profit (excluding interest income and expenses) reached 730 million yuan, marking a 70% growth [2][3] - As of June 30, 2025, the company had unfulfilled orders worth 1.33 billion USD, a year-on-year increase of 58% [1][2] Project and Market Development - The company’s revenue from IND pre-stage projects was 1.12 billion yuan (41%), while IND post-stage revenue was 1.58 billion yuan (59%) in H1 2025 [3] - North America accounted for 1.39 billion yuan of revenue in H1 2025, increasing its share from 49% in H1 2024 to 52%, while revenue from China decreased from 26% to 18% [3] - The company signed a record number of new projects in H1 2025, with a total of 858 drug discovery projects completed, including 59 projects transitioning from drug discovery to CMC [3] Capacity Expansion and Operational Efficiency - The new facility in Wuxi began operations in May 2025, and the DP3 formulation workshop started GMP operations in July 2025 [3] - The company is accelerating capacity expansion, with plans for new production lines to be launched every six months, aiming to double the production capacity of conjugated formulations and payload linkers by 2029 [3][5] - Capital expenditure for 2025 is projected at 1.56 billion yuan, with significant investments in the Wuxi and Singapore facilities [3][5] Future Outlook - The global ADC market is projected to reach 66.2 billion USD by 2030, indicating strong growth potential for the company [4] - The company expects to achieve over 45% revenue growth for the full year of 2025, driven by a robust pipeline and increasing market share [5] - Revenue forecasts for 2025-2027 are estimated at 6.01 billion yuan, 7.82 billion yuan, and 9.70 billion yuan, with corresponding growth rates of 48%, 30%, and 24% [6]

证券研究报告·海外公司点评·药品及生物科技(HS) 药明合联（02268.HK） 2025 年中报点评：业绩超预期，资本开支持 续加码，高成长性确定性强 买入（维持） | Table_EPS] [盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 2,169 | 4,052 | 6,108 | 8,199 | 10,305 | | 同比（%） | 114.26 | 86.82 | 50.72 | 34.24 | 25.68 | | 归母净利润（百万元） | 283.54 | 1,069.62 | 1,596.30 | 1,998.67 | 2,758.31 | | 同比（%） | 82.07 | 277.24 | 49.24 | 25.21 | 38.01 | | Non-GAAP 净利润（百万元） | 412.26 | 1,174.01 | 1,696.30 | 2,198.67 | 2,908.31 | | 同比（%） | 112.10 | 184.77 ...

H1 业绩超预期，长期 CAPEX 彰显信心 药明合联(2268) [Table_Market] 交易数据 药明合联 2025 年半年报点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | | | 周航(分析师) | 021-23185606 | zhouhang@gtht.com | S0880525040077 | [当前价格 Table_CurPrice] (港元)： | 57.70 | | 陈铭(研究助理) | 021-23219164 | chenming7@gtht.com | S0880125042235 | | | | 吴晗(分析师) | 010-83939773 | wuhan3@gtht.com | S0880523080005 | | | 本报告导读： 药明合联业绩持续保持高速增长，预计到 2029 ...

⚫ 考虑到公司短期在手订单充足、产能稳步释放、积极开拓业务，同时加码长期资本 开支，我们上调收入、毛利率和费用率预测，调整公司 2025-2027 年每股收益分别 为 1.29、1.78、2.45 元（25-27 年原预测为 1.05、1.41 和 1.91 元），考虑到公司是 全球 ADC CRDMO 龙头，长期发展潜力大，我们采取 DCF 估值法，给予目标价格为 65.82 港元（按照港元兑人民币 1:0.9125 汇率测算），维持"买入"评级。 药明合联 02268.HK 公司研究 | 中报点评 上调全年收入指引，加码长期资本开支 ——药明合联 2025 年中报点评 核心观点 盈利预测与投资建议 风险提示 海外政策和市场环境、ADC 行业增速不及预期、CXO 行业竞争加剧、汇率和估值等风险 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 2124 | 4052 | 5876 | 8062 | 10693 | | 同比增长 (%) | 114.4 ...

Macro Insights - The economic growth rate in August is expected to be supported by exports and consumption policies, despite a significant slowdown in the real estate sector, with a target of 5% annual growth remaining achievable [1][15][12] - The industrial added value in July grew by 5.7% year-on-year, with the manufacturing sector showing resilience, particularly in high-tech products and equipment manufacturing [12][13] - Fixed asset investment growth slowed to 1.6% year-on-year in the first seven months, primarily due to a decline in real estate investment, which fell by 12% [13][14] Strategy Insights - Current channels for resident capital entering the market include increasing financing balances and active personal investor accounts, leading to a positive feedback loop in the market [2] - The "anti-involution" market trend can be analyzed through policy expectations and real-world transmission, indicating a shift from theme-driven to profit-driven market dynamics [2] - The technology and small-cap sectors are expected to continue outperforming as more external funds enter the market [2] Industry Reports - The consumer electronics sector is anticipated to see significant opportunities with the upcoming release of new products, particularly in AI-related applications [8] - The coal mining industry is experiencing a continuous improvement in fundamentals, with the price of thermal coal expected to rise [8] - The healthcare sector, particularly innovative drugs, is projected to maintain a positive outlook due to improved profitability [8]

行 业 及 产 业 海外消费服务 2025 年 08 月 22 日 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 周文远 A0230518110003 zhouwy@swsresearch.com 贾梦迪 A0230520010002 jiamd@swsresearch.com 胡梦婷 A0230524060004 humt@swsresearch.com 研究支持 胡梦婷 A0230524060004 humt@swsresearch.com 联系人 胡梦婷 (8621)23297818× humt@swsresearch.com 港股医药中报业绩期，关注业绩超预期标的 看好 ——海外消费周报（20250815-20250821） 本期投资提示： ⚫ 海外医药：港股医药中报业绩期，关注业绩超预期标的 国内医药公司 1H25 业绩：恒瑞医药：1H25，公司实现收入 157.61 亿元，同比增长 15.9%；净利润 44.55 亿元，同比增 长 29.9%；归母净利润 44.50 亿元，同比 ...